Skip to main content
SpringerLink
Log in
Book cover

Stem Cell Transplantation for Hematologic Malignancies pp 469–484Cite as

Nonmyeloablative Transplantation

  • Chapter

Part of the book series: Contemporary Hematology ((CH))

Abstract

The myeloablative doses of chemotherapy and total-body irradiation (TBI) used in allogeneic hematopoietic stem cell transplant (a11oHSCT) can produce considerable morbidity and mortality, particularly in older or medically infirm patients. These toxicities restrict this treatment to patients who are younger than 50 yr of age and in good medical condition (1). Patients older than 50 yr account for only 10% of those followed by the International Bone Marrow Transplant Registry (2). Such a restriction is problematic in that many hematologic malignancies for which a11oHSCT may be curable typically are present after age 50 (3).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Molina A7, Storb RF. Hematopoietic stem cell transplantation in older adults. In: Rowe JM, Lazarus HM, Carella AM, eds. Handbook of Bone Marrow Transplantation, 1st ed. London: Martin Dunitz, 2000: 111–137.

    Google Scholar 

  2. Horowitz MM, Keating A. Report on state of the art in blood and marrow transplantation the IBMTR/ ABMTR summary slides with guide. IBMTR/ABMTR Newslett 2000: 7: 3–10.

    Google Scholar 

  3. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23–47.

    Article  PubMed  Google Scholar 

  4. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. NEngl JMed 1975;292: 832–843, 895–902.

    Google Scholar 

  5. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073.

    Article  PubMed  CAS  Google Scholar 

  6. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–1533.

    Article  PubMed  CAS  Google Scholar 

  7. Gorin NC, Labopin M, Fouillard L, et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. Bone Marrow Transplant 1996; 18: 111–117.

    PubMed  CAS  Google Scholar 

  8. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217–223.

    Article  PubMed  CAS  Google Scholar 

  9. Fefer A, Sullivan KM, Weiden P, et al. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. In: Truitt RL, Gale RP, Bortin MM, eds. Cellular Immunotherapy of Cancer. Edited by. New York: Alan R. Liss, 1987: 401–408.

    Google Scholar 

  10. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    PubMed  CAS  Google Scholar 

  11. Sullivan KM, Fefer A, Witherspoon R, et al. Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. In: Truitt RL, Gale RP, Bortin MM, eds. Cellular Immunotherapy of Cancer. New York: Alan R. Liss, 1987: 391–399.

    Google Scholar 

  12. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720–1728.

    PubMed  CAS  Google Scholar 

  13. Ringden O, Horowitz MM. Graft-versus-leukemia reactions in humans. Transplant Proc 1989; 21: 2989–2992.

    PubMed  CAS  Google Scholar 

  14. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310–2318.

    PubMed  CAS  Google Scholar 

  15. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377–3383.

    PubMed  Google Scholar 

  16. Porter DL, Roth MS, McGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100–106.

    Article  PubMed  CAS  Google Scholar 

  17. Kolb H7, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.

    Google Scholar 

  18. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–1268.

    PubMed  CAS  Google Scholar 

  19. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    PubMed  Google Scholar 

  20. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    PubMed  CAS  Google Scholar 

  21. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964–2968.

    PubMed  CAS  Google Scholar 

  22. Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204–3213.

    PubMed  CAS  Google Scholar 

  23. Sykes M, Szot GL, Swenson KA, et al. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nature Med 1997; 3: 783–787.

    Article  PubMed  CAS  Google Scholar 

  24. Manilay JO, Pearson DA, Sergio JJ, et al. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation 1998; 66: 96–102.

    Article  PubMed  CAS  Google Scholar 

  25. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    PubMed  CAS  Google Scholar 

  26. Khouri IF, Keating M, Körbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.

    PubMed  CAS  Google Scholar 

  27. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    PubMed  CAS  Google Scholar 

  28. Nagler A, Slavin S, Varadi G, et al. Allogeneic peripheral blood stem cell transplantation using a fludarabinebased low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021–1028.

    Article  PubMed  CAS  Google Scholar 

  29. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234–3241.

    PubMed  CAS  Google Scholar 

  30. Spitzer TR, McAfee S, Sackstein R, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6: 309–320.

    Article  PubMed  CAS  Google Scholar 

  31. Wäsch R, Reisser S, Hahn J, et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant 2000; 26: 243–250.

    Article  PubMed  Google Scholar 

  32. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419–2425.

    PubMed  CAS  Google Scholar 

  33. Carella AM, Cavaliere M, Lerma E, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol 2000; 18: 3918–3924.

    PubMed  CAS  Google Scholar 

  34. Sandmaier BM, Maloney DG, Gooley T, et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: clinical results of a TBI-based conditioning regimen. Blood 2001;98(Pt 1):742a-743a [Abstract #30931.

    Google Scholar 

  35. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991; 9: 175–188.

    PubMed  CAS  Google Scholar 

  36. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy [review]. J Clin Oncol 1995; 13: 2431–2448.

    PubMed  CAS  Google Scholar 

  37. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755–1759.

    Article  PubMed  CAS  Google Scholar 

  38. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantion by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071–1078.

    Article  PubMed  CAS  Google Scholar 

  39. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 1998; 338: 1272–1278.

    Article  PubMed  CAS  Google Scholar 

  40. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750–758.

    Article  PubMed  CAS  Google Scholar 

  41. Amrolia P, Gaspar HB, Hassan A, et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000; 96: 1239–1246.

    PubMed  CAS  Google Scholar 

  42. Horwitz ME, Barrett AJ, Brown MR, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001; 344: 881–888.

    Article  PubMed  CAS  Google Scholar 

  43. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048–3054.

    PubMed  CAS  Google Scholar 

  44. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

    Article  PubMed  CAS  Google Scholar 

  45. Maris M, Niederwieser D, Sandmaier B, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 2021–2030.

    Article  PubMed  CAS  Google Scholar 

  46. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787–2793.

    PubMed  CAS  Google Scholar 

  47. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312–1322.

    PubMed  CAS  Google Scholar 

  48. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206–4211.

    PubMed  CAS  Google Scholar 

  49. Maloney DG, Sahebi F, Stockerl-Goldstein KE, et al. Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood,in press.

    Google Scholar 

  50. Radich JP, Gooley T, Sanders JE, et al. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant 2000; 6: 272–279.

    Article  PubMed  CAS  Google Scholar 

  51. de Lima M, van Besien KW, Giralt SA, et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin’ s lymphoma. Bone Marrow Transplant 1997; 19: 121–127.

    Article  PubMed  Google Scholar 

  52. Ringdén O, Labopin M, Gorin NC, et al. The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Bone Marrow Transplant 2000; 25: 1053–1058.

    Article  PubMed  Google Scholar 

  53. Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887–892.

    Article  PubMed  CAS  Google Scholar 

  54. Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 1997; 20: 859–863.

    Article  PubMed  CAS  Google Scholar 

  55. Ringdén O, Labopin M, Frassoni F, et al. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Bone Marrow Transplant 1999; 24: 389–396.

    Article  PubMed  Google Scholar 

  56. Bosi A, Laszlo D, Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19: 3675–3684.

    PubMed  CAS  Google Scholar 

  57. Nagler A, Or R, Naparstek E, et al. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol 2000; 28: 1096–1104.

    Article  PubMed  CAS  Google Scholar 

  58. Dey BR, McAfee S, Sackstein R, et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologus stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 604–612.

    Article  PubMed  CAS  Google Scholar 

  59. Devine SM, Sanborn R, Jessop E, et al. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant 2001; 28: 557–562.

    Article  PubMed  CAS  Google Scholar 

  60. Feinstein LC, Sandmaier BM, Maloney DG, et al. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biol Blood Marrow Transplant 2003; 9: 266–272.

    Article  PubMed  Google Scholar 

  61. Carlens S, Remberger M, Aschan J, et al. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biol Blood Marrow Transplant 2001; 7: 31–38.

    Article  PubMed  CAS  Google Scholar 

  62. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412–415.

    Article  PubMed  CAS  Google Scholar 

  63. Andreani M, Nesci S, Lucarelli G, et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000; 25: 401–404.

    Article  PubMed  CAS  Google Scholar 

  64. Andreani M, Manna M, Lucarelli G, et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996; 87: 3494–3499.

    PubMed  CAS  Google Scholar 

  65. Walters MC, Patience M, Leisenring W, et al. Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. Biol Blood Marrow Transplant 1997; 3: 310–315.

    PubMed  CAS  Google Scholar 

  66. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood 2000; 95: 1918–1924.

    PubMed  CAS  Google Scholar 

  67. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22: 1–6.

    Article  PubMed  CAS  Google Scholar 

  68. Georges GE, Storb R, Thompson JD, et al. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood 2000; 95: 3262–3269.

    PubMed  CAS  Google Scholar 

  69. Storb R, Yu C, ZauchaJM, et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999; 94: 2523–2529.

    PubMed  CAS  Google Scholar 

  70. Li S, Thanikachalam M, Pang M, et al. Combined host-conditioning with CTLA4-Ig, tacrolimus, anti-lymphocyte serum, and low-dose radiation leads to stable mixed hematopoietic chimerism. Exp Hematol2001;29:534–541.

    Google Scholar 

  71. Sandmaier BM, Bethge WA, Wilbur DS, et al. Bismuth-213 labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood, 2002; 100: 318–326.

    Article  PubMed  CAS  Google Scholar 

  72. Fuchimoto Y, Huang CA, Yamada K, et al. Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest 2000; 105: 1779–1789.

    Article  PubMed  CAS  Google Scholar 

  73. Bachar-Lustig E, Rachamim N, Li HW, et al. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nature Med 1995; 1: 1268–1273.

    Article  PubMed  CAS  Google Scholar 

  74. Yu XZ, Bidwell S7, Martin PJ, et al. CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol 2000; 164: 4564–4568.

    PubMed  CAS  Google Scholar 

  75. Ito H, Kurtz J, Shaffer J, et al. CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40–CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway. J Immunol 2001; 166: 2970–2981.

    PubMed  CAS  Google Scholar 

  76. Sandmaier BM, Yu C, Gooley T, et al. Haploidentical stem cell allografts after nonmyeloablative therapy in a preclinical large animal model. Blood 1999; 94 (suppl 1): 318a [Abstract 1424].

    Google Scholar 

  77. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    Article  PubMed  CAS  Google Scholar 

  78. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231–1237.

    Article  PubMed  CAS  Google Scholar 

  79. Heldal D, Tj onnfj ord GE, Brinch L, et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000; 25: 1129–1136.

    Article  PubMed  CAS  Google Scholar 

  80. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702–3709.

    PubMed  CAS  Google Scholar 

  81. Mohty M, Faucher C, Vey N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Tranplant 2000; 26: 251–255.

    Article  CAS  Google Scholar 

  82. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978–1985.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Lyle C. Feinstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brenda M. Sandmaier MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Feinstein, L.C., Sandmaier, B.M. (2004). Nonmyeloablative Transplantation. In: Soiffer, R.J. (eds) Stem Cell Transplantation for Hematologic Malignancies. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-733-8_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-733-8_22

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6588-5

  • Online ISBN: 978-1-59259-733-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation